PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, Formula (I), wherein, the group X-Y is -NHSO2-; Z is a monocyclic or polycyclic cycloalkyl group or a monocyclic or polycyclic heterocycloalkyl group, each of which is optionally substituted by one or more groups selected from haloalkyl, alkyl, alkenyl, alkynyl and -(CR16R17)mR18, where m is 0 to 6; L is a direct bond or a group (CR14R15)n, where n is 1 or 2; R1 is H, CN, Cl or F or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, halo, alkoxy and alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl, SO2NR12R13, heteroaryl, CONR10R11 and alkyl, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R9 is selected from H, alkyl and halo; Rio, R1, R12 and R13 are each independently H or alkyl; R14 and R15 are each independently H, halo or alkyl; R16 and R17 are each independently H, halo, haloalkyl or alkyl; and each R18 is independently selected from OH, CN, alkoxy and halo. Further aspects of the invention relate to such compounds for use in the field of immune-oncology and related applications.